home / stock / nvo / nvo articles

NVO Articles, Novo Nordisk A/S - From 03/06/24

Stock Information
Company Name: Novo Nordisk A/S
Stock Symbol: NVO
Market: NYSE
Website: novonordisk.com
Menu
NVO NVO Quote NVO Short NVO News NVO Articles NVO Message Board
Get NVO Alerts

News, Short Squeeze, Breakout and More Instantly...
Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk | Benzinga

Eli Lilly (NYSE:LLY) is aggressively pursuing collaborations with outsourcing partners to ramp up the production of its obesity drug, Zepbound...
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic | Benzinga

As President Joe Biden prepares for his State of the Union address on Thursday, he's expected to touch on several key issues including Bidenom...

Why Are Dialysis Provider Stocks Trading Higher On Tuesday? | Benzinga

Tuesday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the kidney outcomes trial, FLOW. The trial achieved its primary e...

Novo Nordisk Says Famed Diabetes Medicine Ozempic Reduces Risk Of Kidney Disease Progression, Data Shows (UPDATED) | Benzinga

Editor’s note: This story has been updated to reflect a new press release issued by Novo Nordisk that clarifies details around the primary en...
Novo Nordisk Says Famed Diabetes Medicine Ozempic Reduces Risk Of Kidney Disease Progression, Data Shows | Benzinga

Tuesday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the kidney outcomes trial, FLOW. The study compared inj...

Jim Cramer Says Nvidia, Eli Lilly, Novo Nordisk Are Not Overvalued: 'Will Be Ready To Buy If This Market Sells Off' | Benzinga

CNBC host Jim Cramer advised investors to gear up for a potential market sell-off, asserting that they should be ready to make purchases if underva...

Eli Lilly's Commercial Moat, Competitor Landscape: BofA Emphasizes Strength in Incretin Space, Undervalued Assets | Benzinga

BofA Securities says Eli Lilly and Company (NYSE:LLY) remains a top choice in Biopharma analysis, boasting a remarkable year-to-date...
Ozempic, Wegovy And Other Weight-Loss Drugs Won't Solve Global Obesity Crisis Affecting 1B People, WHO Warns | Benzinga

The World Health Organization (WHO) has cautioned that the increasing global obesity crisis, which now affects over a billion people, cannot be res...

Here's How Much $100 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today | Benzinga

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 7.05% on an annualized basis producing an average annual return of 17...

Viking Therapeutics' Weight Loss Study Data Outperformed Novo Nordisk, Eli Lilly Studies, Analysts Say | Benzinga

Viking Therapeutics Inc (NASDAQ:VKTX) recently released top-line results from a successful Phase 2 weight loss trial. Patients receiving VK2735 d...
Previous 10 Next 10